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Abstract Natriuretic peptides (NPs) represent a critical pathway in heart failure (HF). We explored genetic determinants
of pharmacodynamic effects of B-type NP (BNP) and changes
in plasma cyclic guanosine monophosphate (cGMP) and
blood pressure (BP). HF patients (n=135) received recombinant human BNP (nesiritide) at standard doses, and plasma
cGMP levels were measured at baseline and during infusion.
We tested the association of 119 single nucleotide polymorphisms (SNPs) in 4 candidate genes (NPR1, NPR2, NPR3,
and membrane metallo-endopeptidase (MME)) with the
change in cGMP and BP. Gene-based testing for association
of genetic variation with endpoints was significant only for
MME. Upon individual SNP testing, two loci in MME were
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associated with ΔcGMP; another (rs16824656) showed association with BP change. In summary, the pharmacodynamic
effects of BNP vary substantially in HF patients and are associated with genetic variation in MME. MME genetic variation
may be an important determinant of NP-mediated effects in
humans.
Keywords Natriuretic peptide . Heart failure . Drug
metabolism . Pharmacogenetics . Genetic polymorphisms

Abbreviations
BP
Blood pressure
BPM
Beats per minute
BNP
B-type natriuretic peptide
cGMP
Cyclic guanosine monophosphate
DBP
Diastolic blood pressure
GMP
Guanosine monophosphate
HF
Heart failure
MME
Membrane metallo-endopeptidase
NEP
Neutral endopeptidase
NP
Natriuretic peptide
NPR
Natriuretic peptide receptor
NPRC
Natriuretic peptide receptor C
PGBNP Pharmacogenetics of N-type natriuretic peptide
SBP
Systolic blood pressure
SNP
Single nucleotide polymorphism

Introduction
There have been numerous advances in the treatment of
heart failure (HF) over the last two decades, but despite
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this, it remains a critical public health problem with a
high prevalence, substantial morbidity and mortality, and
enormous associated costs [1]. The natriuretic peptide
(NP) system, particularly B-type NP (BNP), has
emerged as a critical factor in HF. It is helpful in establishing diagnosis and prognosis, plays an important
role in the pathophysiology, and has even led to novel
therapeutic agents [2–5]. However, there is still an incomplete understanding of the impact and inner workings of the NP system, particularly the marked variability in NP system function across the broad spectrum of
HF patients [6]. For example, it is clear that BNP
levels, rates of BNP elimination, and clinical response
to extrinsic NP (e.g., nesiritide, carperitide) vary substantially among HF patients [4, 7, 8]. Part of this variability is genetic in origin; BNP levels are heritable [9],
variation in NP pathway genes is associated with differences in BNP production [10, 11] and cardiovascular
phenotypes [12–15], and our group recently showed that
BNP clearance rate appears to be affected by genetic
variation [7]. An important related question is whether
the pharmacodynamic impact of BNP varies with genetic background. This would have obvious implications in
terms of understanding the HF disease process, as well
as potentially influencing the effectiveness of interventions targeting the NP system.
From a molecular standpoint, there are primarily two
effector receptors and two clearance mechanisms previously identified for NPs; NP receptor (NPR) A (gene name
NPR1), B (NPR2), and C (NPR3) and membrane metalloendopeptidase (aka neutral endopeptidase [NEP]), encoded
by the gene MME (Fig. 1) [16–18]. NPRA and NPRB are
transmembrane guanylate cyclases that generate cyclic
guanosine monophosphate (cGMP), the key second

Fig. 1 Schematic of BNP processing. NPRC natriuretic peptide receptor
C, MME membrane metallo-endopeptidase, BNP B-type natriuretic
peptide
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messenger, which is thought to ultimately mediate most
physiologic effects, after NP binds to the receptor. MME
enzymatically degrades NP (and other peptides) to predominantly inactive forms. NPRC is a non-catalytic
NPR, which shares homology with the other NPRs in
the extracellular and transmembrane portions, but lacks
the intracellular guanylate cyclase domain. It is thought
that its primary role is in peptide internalization and clearance although effector roles have also been proposed.
With these as our target genes, the goal of the present
study was to systematically assess whether genetic variation in these candidates impacts the physiologic effects of
BNP. To do this, we studied HF patients infused with
exogenous BNP (nesiritide) and quantified the response
by measuring the change in plasma cGMP levels (primary
end point) as well as in blood pressure (BP).

Methods
Patients and Sample Collection
The primary study, Pharmacogenetics of BNP (PGBNP), was
an investigator-initiated National Institutes of Healthsponsored study centered at Henry Ford Hospital in Detroit,
MI. Patients were enrolled at two sites: Henry Ford Hospital
(88 subjects) and Butterworth Hospital (13 subjects) in Grand
Rapids, MI. The study was approved by the Henry Ford Hospital and Butterworth Hospital institutional review boards, and
written informed consent was obtained from all patients. A
total of 101 patients with a history of HF who were receiving
nesiritide either as part of clinical care (hospitalized HF patients) or only for the purposes of the study (ambulatory
chronic HF patients) were included. Subjects with baseline
systolic BP (SBP) less than 110 mmHg or with end-stage renal
disease were excluded. Patients received intravenous
nesiritide at standard doses: 2 mcg/kg bolus (not required for
participation—i.e., the bolus could be held at the discretion of
the physician) followed by 0.01 mcg/kg/min continuous infusion. Patients were monitored for 1 h prior to bolus and an
additional 2 h following initiation of nesiritide. Patients were
monitored for at least 1 h after discontinuation (if the drug was
stopped). Blood samples were drawn at baseline and at 2 h of
continuous infusion. BP was monitored every 15 min
throughout the study. Six patients were not included in the
final analysis because either they did not receive the study
drug (excluded during baseline phase due to vital signs) or
samples could not be collected, leaving 95 subjects for analysis. All patient samples were centrifuged, aliquoted, and frozen within 30 min and were stored at −70 °C until batch
testing could be performed.
In order to increase our sample size and power, we also
pooled data from the Assessment of Biomarkers and
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Cardiorenal Syndrome Heart Failure Trial (ABCHF) study
[19], the design and primary results of which have been previously published [20]. Briefly, this was an investigatorinitiated clinical trial which randomized patients with exacerbated HF to receive nesiritide or nitroglycerin and collected
blood samples, BP, and other data at baseline through 48 h of
infusion. Patients were also consented for genetic analyses at
the time of study. Patient samples and data from 43 subjects in
the nesiritide arm were examined; after missing data or samples were excluded, 40 subjects had analyzable data and were
included in the final analysis for the present work. Sample
handling and processing for cGMP and genotyping was performed the same as in the PGBNP. BP measurements were
taken at baseline and hourly through the study period. Analyses were performed on the baseline measure, and mean BP at 1
and 3 h, to be as consistent as possible with the PGBNP study.
Blood samples for cGMP were collected at baseline and 24 h.
Cyclic Guanosine Monophosphate Quantification
All cGMP assays were performed in the Cardiovascular Research Laboratory at Henry Ford Hospital. Commercially
available kits from Arbor Assays (Ann Arbor, MI) were used
according to standard processes. Proteins in stored plasma
samples were precipitated by adding 95 % alcohol, and the
resulting lyophilized supernatant was acetylated; cGMP was
assayed as described in the assay kit. Values of cGMP were
expressed as picomoles per milliliter. Among the total cohort
of 135 patients, a cGMP level (either baseline or infusion)
could not be obtained in 9 subjects (2 from PGBNP and 7
from ABCHF), so that paired sample results were available
on a total of 126 individuals.
Genotyping
DNA samples were genotyped using a custom Illumina
Goldengate® array that contained candidate-gene coverage
relevant to HF including focused attention on the genes of
interest to the NP pathway. Single nucleotide polymorphisms (SNPs) were chosen for the array by attempting to
include all coding variants and also utilizing HAPMAP to
select optimal noncoding (“tag”) variants to capture blocks
with minor allele frequency (>0.1 prevalence) in whites or
African-Americans within the gene regions of interest. After processing requirements for the Goldengate technology
and quality control of genotyping, 119 SNPs in the 4 candidate genes of interest, NPR1 (8), NPR2 (18), NPR3 (52),
and MME (41), were available for analysis. Genotyping
calls were made using GenomeStudio software automatic
algorithms (Illumina, San Diego, CA), and then individual
SNPs were reviewed manually. Sample call rates were
greater than 90 %, and none of the SNPs analyzed deviated
significantly from Hardy-Weinberg equilibrium.
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Statistical Analysis
The primary analysis was a SNP-wise test of association
with change in cGMP levels (ΔcGMP) for all SNPs genotyped using linear regression, adjusted for self-identified
race, hospitalization status (inpatient vs. ambulatory), and
bolus use. We estimated the association between genotype
and outcome for each SNP within each cohort separately
(PGBNP or ABCHF), and significant heterogeneity was observed using Cochran’s Q test [21]. We then combined the
estimates using the random effect model for each SNP as
shown below:
yi ¼ μ þ θi þ εi
where yi is the observed effect size for each cohort i, μ is the
overall mean, and θi is the random effect for the cohort
which is normally distributed with mean 0 and variance τ 2
representing between-cohort variance. εi ∼N(0,s2i ) in which
s2i represents within-cohort variability. τ2 was estimated
using the DerSimonian-Laird method [22]. We similarly examined genotype associations with the secondary end points
of (1) change in SBP and (2) change in diastolic BP (DBP).
Since BP was measured every 15 min throughout the study,
we used the average SBP over the infusion period minus the
average SBP over the baseline period as the change in SBP
(i.e., average SBP during infusion −average SBP during
baseline=change in SBP). Similarly, the average DBPs over
the same two periods were used to calculate the difference in
DBP due to nesiritide infusion. In order to try to assess
which specific genes may be key contributors to pharmacodynamic outcomes (as opposed to attempting to identify the
individual SNP), we also performed a gene-wise analysis in
which the p values of all SNPs across each gene were combined using Simes’ procedure into a single p value [23].
Analyses were performed using PLINK, R, and SAS (SAS
Institute, NC). Since the nature of the study was exploratory
with inherent challenges regarding statistical power for genetic effects, we considered p values less than 0.05 significant,
without formal adjustment for multiple comparisons. For clarity, we also present the false discovery rate (Hochberg method
[24]) for each finding of potential interest and considered 0.1
to be significant [25]. We calculated power using proc power
in SAS (two sample means). Inputting the achieved sample
size of 135, and taking the standard deviation of ΔcGMP
change from a previous published study [21], and group proportions of 4.26:1 (reflecting a minor allele frequency [MAF]
of 0.1) and 1:1 (reflecting MAF 0.3), our estimated power to
detect a 50 % relative difference in ΔcGMP is 89–99 % for
MAF 0.1 to 0.3, respectively. The study was not designed or
sized to achieve standard power in assessing changes in BP.
Using the standard deviation measured in ΔSBP in a previous
study [22] and our cohort size, we again estimated power to
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detect a 50 % change using PROC POWER; this was between
38 and 56 % for MAF of 0.1 to 0.3, respectively.

Results
The overall study included 135 HF patients with a mean age of
65 (±15)years; 35 % were female and 60 % were non-white.
The baseline characteristics of each of the 2 cohorts (95 subjects from the PGBNP study and 40 from the ABC study) are
shown in Table 1. In total, 64 subjects were hospitalized for
HF at the time of study entry and received nesiritide by clinical
indication, with the remaining 71 subjects being patients with
a history of stable chronic HF that received nesiritide for study
purposes only.
Infusion of nesiritide was associated with a significant increase in plasma cGMP and decreases in both SBP and DBP.
The mean change in cGMP from baseline to steady-state infusion was 7.25±8.23 pmol/ml (p<0.0001); the distribution is
depicted in Fig. 2. SBP declined on average 7.3 mmHg
(p<0.0001) while DBP declined 3.5 mmHg (p<0.0001). As
expected, there was no observed impact on heart rate
(↑0.94 beats per minute (bpm), p=0.18). There was also no
significant difference in the sodium excretion rate (p=0.26).
Interestingly, ΔcGMP was poorly correlated with changes in
BP. For example, the Pearson correlation coefficient for
ΔcGMP with ΔSBP was −0.045 (p=0.61).
The changes in cGMP and BP were also examined according to age, gender, race, body mass index, creatinine (continuous variables dichotomized at the median), and use of a bolus. These results are summarized in Table 2, and characteristics with significant association to endpoints are depicted in
supplemental Figure 1. Non-white race was associated with
ΔcGMP (p=0.038), such that non-white patients showed a
greater increase in cGMP compared to white patients. In

Table 1

contrast, change in SBP and DBP in response to infused
nesiritide was less in non-whites compared to their white
counterparts (5 vs. 10 mmHg reduction; p=0.019). Inclusion
of a bolus dose appeared to have no effect on ΔcGMP (7.23
vs. 7.25, p=0.99), but it did affect BP and was associated with
an additional 9-mmHg reduction in SBP (p=0.0003).
Genetic Associations of Pharmacodynamic Response
to Infused BNP
Examination of 119 SNPs in the 4 candidate genes and the
association with the pharmacodynamic phenotypes of interest
was undertaken. Linkage maps of each gene with an associated heat map of phenotypic associations are depicted in Fig. 3.
Gene-wise tests of association were performed by using
Simes’ procedure to calculate a single p value for overall variation in each candidate gene. Only MME appeared to be of
interest, showing a trend for ΔcGMP (p=0.09) and significant
associations with ΔSBP and ΔDBP (p=0.004 and 0.003, respectively), while all the other candidates were not significant.
In terms of individual SNPs, there were two SNPs in
MME that had statistically significant associations with
ΔcGMP: rs9829347 (p = 0.0037) and rs9864287 (p =
0.0069). These two SNPs are in high linkage disequilibrium (D′ = 0.97); they appear to both represent the
same linkage block, as can be seen in Fig. 3, and are
thus unlikely to be two independent findings. The full
linear regression analysis is shown in Table 3 (Forest
plot in supplemental Figure 2), and boxplots of each
endpoint for each SNP are depicted in Fig. 4. The
stronger association was with rs9829347, which carried
a 2.5-pmol/ml difference in ΔcGMP per G allele (1.38fold difference). However, this association did not meet
multiple comparison adjustment significance (false discovery rate (FDR) = 0.39). This genotype was also

Baseline characteristics

Characteristics

PGBNP (cohort 1, N=95)

ABCHF (cohort 2, N=40)

p

Age (years), mean±SD
Female gender, N (%)
Non-white race, N (%)
Ejection fraction ≥50 %, N (%)
Mean ejection fraction (among those <50 %), N (%)
Creatinine (mg/dl), mean±SD
Body mass index (kg/m2), mean±SD

63±16
29 (31 %)
47 (49 %)
25 (26 %)
26 %±11
1.38±0.54
32.6±7.9

69±14
18 (45 %)
34 (85 %)
10 (25 %)
25 %±10
1.27±0.43
30.06±11.7

0.036
0.11
0.0001
0.696
0.87
0.87
0.175

Inpatient status, N (%)
Bolus used, N (%)

25 (26 %)
82 (86 %)

40 (100 %)
24 (60 %)

<0.0001
<0.0001

Statistical tests are t test or chi-square as appropriate
ABCHF Assessment of Biomarkers and Cardiorenal Syndrome Heart Failure Trial, PGBNP Pharmacogenetics of BNP, SD standard deviation
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Fig. 2 Histograms and boxplots of change in cGMP by cohort. cGMP cyclic guanosine monophosphate

associated with changes in SBP (p = 0.017) and DBP
(p=0.0039) but not in the anticipated direction relative
Table 2 Mean change in
outcome measures by subgroups

to ΔcGMP (i.e., they were not inversely correlated).
Similarly, rs9864287 was associated with DBP

Characteristic

ΔcGMP (pmol/ml)

Overall
Female
Male
Non-white
White
EF low
EF high
Age low
Age high
BMI low
BMI high
Creatinine low
Creatinine high
Bolus
No bolus
In-hospital
Ambulatory

7.25 (±8.2)
6.73
7.51
8.39
5.54
7.21
7.35
8.61
6.18
6.45
8.30
7.85
6.71
7.25
7.23
5.7
8.46

p

0.62
0.038
0.93
0.11
0.19
0.45
0.99
0.09

ΔSBP (mmHg)
−7.31 (±12.5)
−5.01
−8.54
−5.29
−10.3
−6.89
−8.86
−7.86
−6.87
−6.01
−9.04
−7.15
−7.48
−1.02
−9.68
−3.83
−10.5

p

0.12
0.021
0.43
0.65
0.165
0.88
0.0003
0.0017

ΔDBP (mmHg)
−3.5 (±9.2)
−4.55
−1.55
−2.28
−5.35
−3.04
−4.92
−4.34
−2.84
−2.65
−4.64
−3.61
−3.41
0.44
−4.9
−1.09
−5.75

p

0.071
0.043
0.31
0.35
0.22
0.89
0.0028
0.0035

All p values in the table are from t tests
ΔcGMP change in cyclic guanosine monophosphate, ΔDBP change in diastolic blood pressure, ΔSBP change in
systolic blood pressure, BMI body mass index, EF ejection fraction

550

J. of Cardiovasc. Trans. Res. (2015) 8:545–553

rs9864287
rs982934
rs16824656

Fig. 3 Linkage disequilibrium plot of each candidate gene and heat map
of p values for genetic variants’ association with cGMP, SBP, and DBP.
NPR natriuretic peptide receptor, MME membrane metalloendopeptidase, cGMP cyclic guanosine monophosphate, SBP systolic
blood pressure, DBP diastolic blood pressure. The directionality of the

beta coefficients (positive or negative) refers to the correlation to a
specific allele and is given so that the reader can tell which direction the
three endpoints are changing relative to each other (i.e., to understand
whether the changes for cGMP vs. BP are moving in the same direction or
opposite directions)

J. of Cardiovasc. Trans. Res. (2015) 8:545–553
Table 3
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Results of full linear regression models for ΔcGMP

SNP

rs9864287

rs9829347

rs16824656

Factor

PGBNP

ABCHF

Meta-analysis

Coef.

95 % CI

p

Coef.

95 % CI

p

Coef.

95 % CI

p

Genotype
Race

2.22
3.92

0.52, 3.92
1.36, 6.49

0.012
0.004

3.14
9.18

−3.74, 10.01
−4.74, 23.1

0.379
0.206

2.27

0.62, 3.92

0.007

Bolus

2.82

−0.9, 6.54

0.142

−6.64

−15.15, 1.86

0.136

Inpatient
Genotype

−2.51
2.53

−5.54, 0.52
0.8, 4.27

0.108
0.005

1.98

−5.39, 9.35

0.602

2.5

0.81, 4.20

0.004

Race
Bolus

3.98
3.08

1.41, 6.55
−0.62, 6.79

0.003
0.107

7.58
−6.74

−5.98, 21.14
−15.44, 1.96

0.282
0.139
1.13

−5.52, 7.77

0.739

Inpatient

−2.66

−5.67, 0.35

0.087

Genotype
Race

−1.52
2.45

−3.96, 0.92
0.13, 4.78

0.226
0.043

5.46
5.02

−1.69, 12.61
−6.64, 16.68

0.145
0.405

Bolus
Inpatient

2.33
−2.80

−1.31, 5.98
−5.79, 0.20

0.214
0.071

−4.60

−13.17, 3.98

0.302

(p=0.0096) but not SBP. There was one other locus in
MME which had a more borderline association with
ΔcGMP: rs1126073 (p=0.029, FDR 0.93).
While change in cGMP was our primary endpoint, we also
explored changes in BP with BNP infusion. There were a
number of variants showing significant associations with
change in BP (Supplemental Table), and most of these, particularly the most statistically significant SNPs, were within
MME. Four variants in MME showed significant associations
to ΔSBP with BNP infusion. The strongest was rs16824656
(p=0.00015, FDR=0.017). The same SNP was also related to
ΔDBP (p=0.00011, FDR=0.012). Interestingly, this SNP had
no significant association to ΔcGMP (bottom of Table 3, p=
0.74), perhaps due to disparate cGMP trends in the two cohorts (right panel of Fig. 4). Three other SNPs had more borderline associations with ΔSBP (rs9829347, rs701109,
rs3773878) with p values ranging from 0.017 to 0.029 and
all with FDR=0.77. There were no significant variants in the
other genes for ΔSBP. Diastolic BP change showed 15 variants with significant associations (Supplemental Table 1),
from MME, NPR2, and NPR3. Interestingly, the strongest
and the only one with significance by FDR was rs16824656,
same as noted above for ΔSBP.

Discussion
The aim of the present study was to better understand the
variability in the pharmacodynamic response to BNP, taking
advantage of the existence of human recombinant BNP as a
pharmacologic agent (nesiritide) to assess the acute response
in humans with HF. These data demonstrate substantial variability in the second messenger response, which is related to
self-identified race as well as specific genetic variants,

particularly in MME. We did not detect a corresponding
change in BP associated with the genotypes associated with
ΔcGMP, but we were underpowered for those end points and
did find additional variants associated with ΔBP alone. To our
knowledge, this study is one of the largest of its kind, interrogating the impact of genetic variation on NP system physiology in humans. This is an important question as the NP system
is a key player in the development, diagnosis, prognosis, and
treatment of HF.
Overall, MME appears to be the best candidate gene for
modulating the response to NPs of those examined in this
study. It was the only gene of the four examined that was
significant in gene-wise testing and had several strong associations with ΔcGMP and ΔBP. Although the individual variants identified as important to the pharmacodynamic effect
were not the same as from recently published pharmacokinetic
[7] and gene expression [26] analyses, there is significant
linkage disequilibrium (LD) in MME that could partially explain this inconsistency (supplemental Figure 2). Indeed,
some of the loci in the middle LD block of the gene, which
were associated with expression in our previous study
(rs1816558, rs10513469, rs1436630, rs1025192,
rs3773895), show linkage disequilibrium with the 3′ LD block
containing the SNPs associated with pharmacodynamic endpoints (cGMP and BP); specifically, rs1025192, which was
the strongest SNP associate of gene expression, shows LD
with both rs9829347 and rs9864287 (D′=0.54 and 0.64, respectively). Similarly, the linkage block near the 5′ end, which
had several SNP associations to BNP pharmacokinetics in the
previous study (rs989692, rs6798179, rs9834487), does show
some longer range LD with the 3′ block of interest in the
current study. Thus, while no specific variant was functionally
validated, the totality of the data suggests that genetic variation in MME is likely an important determinant of NP system
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Limitations
Our study has several limitations that should be noted. The
study sample size provided adequate power for cGMP but was
underpowered for BP. Nonetheless, identification of a significant correlation between cGMP and genetic variation in
MME can provide a foundation for future studies with larger
sample sizes to assess the impact of genetic variation on BP or
other clinical end points, such as symptoms or outcomes.
While we have examined what were felt to be the key characteristics in describing our cohorts, it is possible that there were
unaccounted differences in the two cohorts that made up this
study and this somehow could have impacted the results. We
attempted to mitigate this concern by accounting for study site
in our models, but residual confounding of unmeasured or
untested variables cannot be definitively excluded. Another
potential limitation is the nonrandomized nature of the study,
raising the possibility that other factors could have contributed
to the changes in cGMP. It is unlikely, however, that other
simultaneous changes drove our findings given the short time
frame of the study and that BNP is a key driver of cGMP.
Finally, this was a candidate gene study, and the sample size
does not provide adequate power to take an unbiased approach. Thus, we could be overlooking other important genetic contributors to NP response.

Conclusions
Cyclic GMP, the second messenger of NPs, is increased in
plasma following BNP infusion, but the magnitude of change
varies substantially across HF patients and is associated with
both self-identified race and specific genetic variants in MME.
Genetic variation in MME likely impacts NP system physiology
and could have implications for the risk of HF development,
disease progression in HF patients, and targeting of therapies.
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no competing
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Fig. 4 Boxplots of cGMP, SBP, and DBP changes for significant
variants. Genotype frequencies are shown on the plots below each
genotype. cGMP cyclic guanosine monophosphate, SBP systolic blood
pressure, DBP diastolic blood pressure

function and the response to pharmacologic interventions directed at it. Overall, the idea that MME is critical to BNP
response in HF is consistent with the PARADIGM-HF trial
[27] results, which showed that inhibiting MME (aka NEP)
improved HF outcomes. It is intriguing to consider whether
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therapy as well.

Ethical Approval All procedures followed were in accordance with the
ethical standards of the responsible committee on human experimentation
(institutional and national) and with the Helsinki Declaration of 1975, as
revised in 2000 [5].
Informed Consent Informed consent was obtained from all individual
participants included in the study.
Funding This research was supported by the National Heart, Lung, and
Blood Institute (Lanfear K23HL085124, R01HL103871; Williams
R01HL079055, R01HL118267; Sabbah PO1HL074237), the National
Institute of Allergy and Infectious Diseases (Williams R01AI079139,
R01AI061774), and the National Institute of Diabetes and Digestive
and Kidney Diseases (Williams R01DK064695).

J. of Cardiovasc. Trans. Res. (2015) 8:545–553

References
1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D.,
Borden, W. B., et al. (2013). Heart disease and stroke statistics—2013
update: a report from the American Heart Association. Circulation,
127(1), e6–e245. doi:10.1161/CIR.0b013e31828124ad.
O'Connor, C. M., Starling, R. C., Hernandez, A. F., Armstrong, P. W.,
Dickstein, K., Hasselblad, V., et al. (2011). Effect of nesiritide in
patients with acute decompensated heart failure. New England
Journal of Medicine, 365(1), 32–43. doi:10.1056/NEJMoa1100171.
Sackner-Bernstein, J. D., Kowalski, M., Fox, M., & Aaronson, K.
(2005). Short-term risk of death after treatment with nesiritide for
decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA, 293(15), 1900–5.
Sackner-Bernstein, J. D., Skopicki, H. A., & Aaronson, K. D.
(2005). Risk of worsening renal function with nesiritide in patients
with acutely decompensated heart failure. Circulation, 111(12),
1487–91.
Choudhary, R., Iqbal, N., Khusro, F., Higginbotham, E., Green, E.,
& Maisel, A. (2013). Heart failure biomarkers. Journal of
Cardiovascular Translational Research, 6(4), 471–84. doi:10.
1007/s12265-013-9465-0.
Egom, E. E. (2015). BNP and heart failure: preclinical and clinical
trial data. Journal of Cardiovascular Translational Research, 8(3),
149–57. doi:10.1007/s12265-015-9619-3.
Lanfear, D. E., Chow, S., Padhukasahasram, B., Li, J., Langholz,
D., Tang, W. H., et al. (2014). Genetic and nongenetic factors
influencing pharmacokinetics of B-type natriuretic peptide.
Journal of Cardiac Failure, 20(9), 662–8. doi:10.1016/j.cardfail.
2014.06.357.
Publication Committee for the VMAC Investigators. (2002).
Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA,
287(12), 1531–40.
Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Corey, D.,
Leip, E. P., et al. (2003). Heritability and genetic linkage of plasma
natriuretic peptide levels. Circulation, 108(1), 13–6.
Costello-Boerrigter LC, G., Ameenuddin, S., Mahoney, D. W.,
Slusser, J. P., Heublein, D. M., et al. (2011). The effect of the
brain-type natriuretic peptide single-nucleotide polymorphism
rs198389 on test characteristics of common assays. Mayo Clinic
Proceedings, 86(3), 210–8. doi:10.4065/mcp.2010.0708.
Lanfear, D. E., Stolker, J. M., Marsh, S., Rich, M. W., & McLeod,
H. L. (2007). Genetic variation in the B-type natriuretic peptide
pathway affects BNP levels. Cardiovascular Drugs and Therapy,
21(1), 55–62. doi:10.1007/s10557-007-6007-5.
Newton-Cheh, C., Larson, M. G., Vasan, R. S., Levy, D., Bloch, K.
D., Surti, A., et al. (2009). Association of common variants in
NPPA and NPPB with circulating natriuretic peptides and blood
pressure. Nature Genetics, 41(3), 348–53.
Kosuge, K., Soma, M., Nakayama, T., Aoi, N., Sato, M., Izumi, Y.,
et al. (2007). A novel variable number of tandem repeat of the
natriuretic peptide precursor B gene’s 5'-flanking region is associated with essential hypertension among Japanese females.
International Journal of Medical Sciences, 4(3), 146–52.

553
14.

15.

16.

17.

18.

19.

20.

21.
22.
23.

24.

25.

26.

27.

Rubattu, S., Bigatti, G., Evangelista, A., Lanzani, C., Stanzione, R.,
Zagato, L., et al. (2006). Association of atrial natriuretic peptide and
type a natriuretic peptide receptor gene polymorphisms with left
ventricular mass in human essential hypertension. Journal of the
American College of Cardiology, 48(3), 499–505.
Nakayama, T., Soma, M., Mizutani, Y., Xinjuan, X., Honye, J.,
Kaneko, Y., et al. (2002). A novel missense mutation of exon 3 in
the type A human natriuretic peptide receptor gene: possible association with essential hypertension. Hypertension Research, 25(3),
395–401.
Stoupakis, G., & Klapholz, M. (2003). Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure. Heart
Disease, 5(3), 215–23.
Lanfear, D. E. (2010). Genetic variation in the natriuretic peptide
system and heart failure. Heart Failure Reviews, 15(3), 219–28.
doi:10.1007/s10741-008-9113-y.
Nakayama, T. (2005). The genetic contribution of the natriuretic
peptide system to cardiovascular diseases. Endocrine Journal,
52(1), 11–21.
Chow, S. L., O'Barr, S. A., Peng, J., Chew, E., Pak, F., Quist, R.,
et al. (2011). Modulation of novel cardiorenal and inflammatory
biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study. Circulation. Heart
Failure, 4(4), 450–5. doi:10.1161/CIRCHEARTFAILURE.110.
958066.
Chow, S. L., O'Barr, S. A., Peng, J., Chew, E., Pak, F., Quist, R.,
et al. (2011). Renal function and neurohormonal changes following
intravenous infusions of nitroglycerin versus nesiritide in patients
with acute decompensated heart failure. Journal of Cardiac Failure,
17(3), 181–7. doi:10.1016/j.cardfail.2010.10.005.
Cochran, W. G. (1950). The comparison of percentages in matched
samples. Biometrika, 37(3-4), 256–66.
DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical
trials. Controlled Clinical Trials, 7(3), 177–88.
Li, M. X., Gui, H. S., Kwan, J. S., & Sham, P. C. (2011). GATES: a
rapid and powerful gene-based association test using extended
Simes procedure. American Journal of Human Genetics, 88(3),
283–93. doi:10.1016/j.ajhg.2011.01.019.
Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., & Golani, I. (2001).
Controlling the false discovery rate in behavior genetics research.
Behavioural Brain Research, 125(1-2), 279–84.
Hao, K., Bosse, Y., Nickle, D. C., Pare, P. D., Postma, D. S.,
Laviolette, M., et al. (2012). Lung eQTLs to help reveal the molecular underpinnings of asthma. PLoS Genetics, 8(11), e1003029.
doi:10.1371/journal.pgen.1003029.
Lanfear, D. E., Sunkara, B., Li, J., Rastogi, S., Gupta, R. C.,
Padhukasahasram, B., et al. (2013). Association of genetic variation
with gene expression and protein abundance within the natriuretic
peptide pathway. Journal of Cardiovascular Translational
Research, 6(5), 826–33. doi:10.1007/s12265-013-9491-y.
McMurray, J. J., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M.,
Rizkala, A. R., et al. (2014). Baseline characteristics and treatment
of patients in Prospective comparison of ARNI with ACEI to
Determine Impact on Global Mortality and morbidity in Heart
Failure trial (PARADIGM-HF). European Journal of Heart
Failure, 16(7), 817–25. doi:10.1002/ejhf.115.

